RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 26, 2014 /PRNewswire/ -- Jardiance ® (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, ...
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 10, 2018 /PRNewswire/ -- Novel results based on data from the landmark EMPA-REG OUTCOME® trial were published in the journal Circulation which suggest that ...
The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. Type 2 diabetes ...
Eli Lilly’s and Boehringer Ingelheim’s Jardiance, approved by the FDA in 2014, is already a blockbuster in the treatment of Type 2 diabetes. But the companies have been aiming to get the drug approved ...
- Empagliflozin is the first and only SGLT2 inhibitor approved for this patient population- More than 5,700 young people are diagnosed with type 2 diabetes annually in the U.S. Jardiance is not ...
INGELHEIM, Germany and RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 7, 2022 /PRNewswire/ -- The DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant ...
A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...
Bottles of the drug Jardiance, made by Eli Lilly and Company, sit on a counter at a pharmacy in Provo FRANKFURT (Reuters) - Boehringer Ingelheim and Eli Lilly said their diabetes drug Jardiance was ...
RIDGEFIELD, Conn and INDIANAPOLIS, Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME ®. This is a long-term clinical trial investigating ...
The scientists found that two medications significantly reduce the risk of developing dementia in life. A new study, published in JAMA Neurology, finds that people with type 2 diabetes who take two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results